An interim U.S. policy covers six peptides, none FDA-approved
CDT Equity (Nasdaq: CDT) welcomed a U.S. interim peptide compounding policy that it believes supports its investment in
DO
By Daniel Okafor · Regulatory Correspondent
Oct 30 08:32 ETSource: Stock Titan
From the source
Read at stocktitan.netAn interim U.S. policy covers six peptides, none FDA-approved
CDT Equity (Nasdaq: CDT) welcomed a U.S. interim peptide compounding policy that it believes supports its investment in Pep’d.
